NCT02914366View on ClinicalTrials.gov

Ambroxol as a Treatment for Parkinson's Disease Dementia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Parkinson's Disease Dementia
Interventions
DRUG

Ambroxol

OTHER

Placebo

Trial Locations (1)

N6C 0A7

Parkwood Institute, London

Sponsors
All Listed Sponsors
collaborator

Weston Brain Institute

OTHER

collaborator

Western University, Canada

OTHER

collaborator

London Health Sciences Centre

OTHER

lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER

NCT02914366 - Ambroxol as a Treatment for Parkinson's Disease Dementia | Biotech Hunter | Biotech Hunter